PRELIMINARY LIST OF PARTICIPANTS

IARC requests that you do not contact or lobby meeting participants, send them written materials, or offer favours that could appear to be linked to their participation. (You may send pertinent written materials to IARC.) IARC will ask participants to report all such contacts and will publicly reveal any attempt to influence the meeting. Thank you for your cooperation.

Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Members
Silvina Arrossi, Center for the Study of State and Society/National Council for Scientific and Technical Research, Argentina
Karima Bendahhou, Casablanca Cancer Registry, Morocco
Johannes Berkhof, Amsterdam University Medical Centers, The Netherlands
Julia Brotherton, Victorian Cytology Service Foundation Limited, Australia¹
Karen Canfell, Cancer Council New South Wales, Australia
Mike Chirenje, University of Zimbabwe College of Health Sciences, Zimbabwe
Michael H. Chung, Aga Khan University, Kenya
Marta del Pino, Hospital Clinic de Barcelona, Spain
Silvia de Sanjose, Program for Appropriate Technology in Health, USA²
Miriam Elfstrom, Karolinska Institutet, Sweden³
Eduardo Franco, McGill University, Canada⁴
Paolo Giorgi Rossi, Local Health Authority of Reggio Emilia, Italy
Chisato Hamashima, Teikyo University/National Cancer Center, Japan
Francoise Hamers, National Public Health Agency, France
Simon Herrington, University of Edinburgh, United Kingdom
Rachel Kupets, University of Toronto, Canada
Anne Mackie, Public Health England Screening, United Kingdom
Philippe Mayaud, London School of Hygiene & Tropical Medicine, United Kingdom
Raúl Murillo, Hospital Universitario San Ignacio, Colombia
Suleeporn Sangrajrang, National Cancer Institute, Thailand
Rengaswamy Sankaranarayanan, Research Triangle Institute International India, India
Mona Saraiya, Centers for Disease Control and Prevention, USA
Robert Smith, American Cancer Society, USA
Nicolas Wentzensen, National Cancer Institute, USA
Fanghui Zhao, Chinese Academy of Medical Sciences, China

Invited Specialists
Marc Arbyn, Sciensano, Belgium⁵
Walter Prendiville, University of Pittsburgh Medical Centre, Ireland (retired)⁶

Representative of national and international health agencies
Carolina Wiesner, Colombian National Cancer Institute, Colombia

¹ Julia Brotherton reports that her unit at VCS Population Health benefits from research funding and equipment from Roche, Seegene, Cepheid, and Becton Dickinson.
² Silvia de Sanjose reports that her unit at PATH benefited from research support from Merck.
³ Miriam Elfstrom reports that her unit at Karolinska Institutet benefited from non-monetary research support from Sanofi Pasteur MSD SNC.
⁴ Eduardo Franco reports being editor-in-chief of the journals Preventive Medicine and Preventive Medicine Reports.
⁵ Marc Arbyn reports that his unit at Sciensano benefits from non-monetary support from manufacturers of human papillomavirus (HPV) assays and devices.
⁶ Walter Prendiville reports holding stocks in NSV, receiving consultancy fees from Koru Auckland, and receiving royalties from Utah Medical Products, Inc. for patent #5951550.
NOTE REGARDING CONFLICTS OF INTERESTS: Each participant first received a preliminary invitation with the request to complete and sign the IARC/WHO Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial and non-financial interests (e.g. public statements and positions related to the subject of the meeting). Official invitations were extended after careful assessment of any declared interests that might constitute a real or perceived conflict of interest. Pertinent and significant conflicts are disclosed here. Information about other potential conflicts that are not disclosed may be sent to the Head of the IARC Handbooks Group at ihb@iarc.fr.

Participants identified as Invited Specialists will not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. The Declarations will be updated and reviewed again at the opening of the meeting.

Posted on 21 April 2020, updated on 3 August 2020